Precision Biosciences (DTIL) Non-Current Deferred Tax Liability (2018 - 2019)
Precision Biosciences' (DTIL) quarterly Non-Current Deferred Tax Liability came in at $1.5 million in Q4 2019, up 149.66% year-on-year from $586000.0 in Q4 2018, and up 149.66% on a QoQ basis from $586000.0 in Q4 2018.
Precision Biosciences (DTIL) Non-Current Deferred Tax Liability (2018 - 2019) Analysis & Trends
Precision Biosciences (DTIL) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $1.5 million in Q4 2019.
- On a quarterly basis, Non-Current Deferred Tax Liability rose 149.66% year-over-year to $1.5 million in Q4 2019; TTM through Dec 2019 was $1.5 million, a 149.66% increase from a year earlier, with the FY2019 full-year figure at $1.5 million, up 149.66% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2019 stood at $1.5 million, up from $586000.0 in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for DTIL reached as high as $1.5 million in Q4 2019 and fell as low as $586000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Precision Biosciences | 178.85 Mn | 150.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1.46 Mn |
| Dec 31, 2019 | 1.46 Mn |
| Dec 31, 2018 | 586,000.00 |
| Dec 31, 2018 | 586,000.00 |